Compound medicinal composition for treating hypertension

Abstract

The invention relates to the field of medicine, in particular to a compound medicinal composition for treating hypertension and application of the composition in preparation of a medicament for treating metabolic syndrome, and aims to well improve the animation prognosis of hypertension patients. The medicinal composition contains the following active ingredients: aliskiren or medicinal salt thereof, pionlitazone or medicinal salt thereof, and rosuvastatin or medicinal salt thereof. Experiments prove that the medicinal composition can control blood pressure at a certain target level, effectively reduce injury of important organs such as cardiovascular system and kidney caused by long-term hypertension, effectively correct simultaneous risk factors such as cardiovascular diseases and improve metabolic disorders and prognosis of the patients, and achieves a good synergistic effect and an unexpected effect on the aspect of treating and controlling various cardio-cerebrovascular complications caused by the hypertension.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a compound pharmaceutical composition for treating hypertension and its use in preparing medicine for treating metabolic syndrome. Background technique [0002] Hypertension is one of the most common cardiovascular diseases, and it is closely related to major diseases such as coronary heart disease and cerebrovascular disease. Although the incidence of hypertension in my country is not as high as that in Western countries, it is increasing year by year Trend, with the continuous improvement of people's living standards and the deterioration of the environment, the number of cardiovascular patients suffering from high blood pressure, high blood fat, and high cholesterol is also increasing. 150 million people, and increase at a rate of 5 million people per year. All countries in the world attach great importance to the study of hypertension from pathogenesis to clinical prevention and treatm...

AI Technical Summary

Problems solved by technology

Li Jie et al pointed out in "Effects of Pioglitazone and Rosuvastatin on Lipid Metabolism and Inflammatory Factors in Rabbit Models of Dyslipidemia" that both pioglitazone and rosuvastatin have the effects of lowering blood sugar, improving blood lipids and anti-inflammation. Different, the combination of the two may have a synergistic and complementary effect on improving blood lipids, but it does not disclose the effects of the two drugs on blood lipids, blood sugar and anti-inflammation after the combined application

[0009] The pharmaceutical compositions containing aliskiren in the above documents have achieved significant curative effects in the process of lowering blood pressure, but usually hypertensive patients will be accompanied by cardiovascular disease or even diabetes, so lipid-lowering therapy should be carried out while treating hypertension , but cardiovascular disease is a high-incidence disease in hypertensive patients. It is not enough to lower blood pressure while treating hypertension. Long-term hypertension may cause damage to important organs such as the cardiovascular system and kidneys. Therefore, antihypertensive treatment not only requires To reduce blood pressure to the target level, and correct existing risk factors such as cardiovascular disease, and select appropriate drugs to improve metabolic disorders and the prognosis of patients, therefore, it is necessary to find a way to effectively control the related diseases while treating hypertension. The occurrence of cardiovascular disease, better multi-drug combination therapy to improve the survival and prognosis of hypertensive patients has become an urgent problem in clinical treatment

Images